Holen Sie sich die Stockscreener-App
15.46
4.07%
-0.655
Vorhandelsmarkt:
15.11
-0.345
-2.23%
Schlusskurs vom Vortag:
$16.11
Offen:
$16.09
24-Stunden-Volumen:
296.27K
Relative Volume:
0.07
Marktkapitalisierung:
$137.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.82M
KGV:
-13.48
EPS:
-1.1465
Netto-Cashflow:
$-8.00M
1W Leistung:
+8.38%
1M Leistung:
+151.71%
6M Leistung:
+814.50%
1J Leistung:
+543.96%
1-Tages-Spanne:
$15.45
$16.50
1-Wochen-Bereich:
$13.65
$20.32
52-Wochen-Spanne:
$0.72
$20.32
Edesa Biotech Inc Stock (EDSA) Company Profile
Firmenname
Edesa Biotech Inc
Sektor
Branche
Telefon
(905) 475-1234
Adresse
100 SPY COURT, MARKHAM, ON
Compare EDSA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
15.46 | 137.33M | 0 | -7.82M | -8.00M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Edesa Biotech Inc Aktie (EDSA) Neueste Nachrichten
Edesa Biotech's Market Cap Up US$44m Following Year Of Insider Stock Buying - simplywall.st
Edesa Biotech (EDSA) CEO awarded 1,159 RSUs and reports updated share holdings - Stock Titan
Edesa Biotech, Inc. Common Shares (EDSA) Stock Price Today & Analysis - Gotrade
Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Decreases By 32.5% - MarketBeat
EDSA - Finviz
Edesa Biotech reports FQ1 net loss of $2.2 million - MSN
EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech? - Stocktwits
Edesa Biotech Stock Soars 54%: What’s Driving the ARDS Drug Rally Now - TechStock²
Edesa (EDSA) Stock: Should You Take Exposure (Investors Pile In) 2026-04-27Community Pattern Alerts - Newser
EDSA Should I Buy - Intellectia AI
Edesa Biotech Reaches US$68m Market Cap Benefiting Insider Stock Buying - Yahoo Finance
EDSA Edesa Biotech Inc. Common Shares posts narrower Q1 2026 loss than consensus forecasts, shares gain on upbeat investor sentiment.Cost Structure - Cổng thông tin điện tử tỉnh Tây Ninh
Edesa Biotech Schedules Phase 2 Vitiligo Study for Mid-2026 - HarianBasis.co
Edesa (EDSA) Stock Insider Buying (Breakout Watch) 2026-04-20Most Discussed Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Edesa Biotech (EDSA) Reaffirms 2026 Clinical Study Timeline for Vitiligo Treatment - Yahoo Finance
Is Edesa (EDSA) Stock a Growth Stock? (Recovers) 2026-04-16MA Crossover - Cổng thông tin điện tử tỉnh Lào Cai
Edesa (EDSA) Stock Real-Time Quote (In Focus) 2026-04-15Trending Stock Ideas - Cổng thông tin điện tử tỉnh Lào Cai
Aug PreEarnings: Can Edesa Biotech Inc sustain earnings growth2026 PreEarnings & Consistent Growth Stock Picks - baoquankhu1.vn
Edesa Biotech (EDSA) CEO receives 2,578-share restricted stock grant - Stock Titan
Aug Opening: Will Edesa Biotech Inc announce a stock splitDividend Hike & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Jobs Data: Is Edesa Biotech Inc still a buy after recent gains2026 Big Picture & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Edesa Biotech (NASDAQ:EDSA) Rating Increased to Hold at Wall Street Zen - MarketBeat
Edesa Biotech (NASDAQ: EDSA) 2026 proxy seeks equity plan boost and director votes - Stock Titan
Edesa Biotech Inc. (EDSA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Edesa (EDSA) Stock Consolidating | Price at $6.14, Up 10.63%Risk Reward Ratio - Cổng thông tin điện tử tỉnh Lào Cai
Edesa Biotech to Showcase Positive ARDS Phase 3 Data at ATS 2026 Summit - TipRanks
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit - GlobeNewswire
Edesa Biotech (NASDAQ:EDSA) Upgraded to Sell at Wall Street Zen - Defense World
Edesa Biotech provides update on EB06 clinical study - TipRanks
Edesa Biotech Confirms Mid-2026 Start for Phase 2 Vitiligo Trial of EB06 - TipRanks
Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment - ChartMill
Vitiligo drug study moves ahead as Edesa picks trial manager - Stock Titan
Gainers Report: Can Edesa Biotech Inc be the next market leader2026 Risk Factors & AI Powered Trade Plan Recommendations - baoquankhu1.vn
If You Invested $1,000 in Edesa Biotech Inc (EDSA) - Stock Titan
PERCEPTIVE ADVISORS LLC Acquires Significant Stake in Edesa Biotech Inc - GuruFocus
PERCEPTIVE ADVISORS LLC Acquires Significant Stake in Edesa Biot - GuruFocus
Volume Recap: Will Edesa Biotech Inc announce a stock split2026 Top Gainers & Weekly High Return Forecasts - baoquankhu1.vn
Bull Bear: Will Edesa Biotech Inc announce a stock splitPortfolio Gains Report & Daily Growth Stock Tips - baoquankhu1.vn
Perceptive Advisors stake: 563,239 shares in EDESA (NASDAQ: EDSA) - Stock Titan
EDSA SEC FilingsEdesa Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Edesa Biotech (EDSA) president buys 2,000 shares in open market - Stock Titan
Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Expands By 9,253.7% - MarketBeat
Edesa Biotech (EDSA) CEO adds 1,000 shares in open-market buy - Stock Titan
Best Biotech Stocks To Follow Today – March 7th - Defense World
Edesa Biotech’s Paridiprubart Trial Success Spurs Market Optimism - StocksToTrade
Edesa Biotech Gains Ground with Positive Clinical and Financial News - timothysykes.com
Will Edesa Biotech Inc. stock attract more institutional investorsPortfolio Performance Report & Weekly Return Optimization Plans - Naître et grandir
Best Biotech Stocks To Follow TodayMarch 7th - MarketBeat
Edesa Biotech Surges Following Promising Clinical Data in ARDS Treatment - StocksToTrade
Edesa Biotech Advances on Promising Drug Trial Results - timothysykes.com
Velan Capital Investment Management LP Increases Stake in Edesa Biotech Inc - GuruFocus
Finanzdaten der Edesa Biotech Inc-Aktie (EDSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):